Intervacc is trading 15.02% down now at €0.06 after broad biotech weakness and defensive risk reduction ahead of Federal Reserve Chair Kevin Warsh’s Jackson Hole policy signals.
- No company-specific announcement was identified for August 31, 2026, or September 1, 2026.
- The latest report showed weaker European Strangvac revenue and continued losses.
- No new negative catalyst directly explaining the decline was identified.